This seems like a typical report on JAT that the market sees at...

This seems like a typical report on JAT that the market sees at the moment. No mention of this years quarterly sales and growth and misses a lot of other good things JAT has done. Its Jatpharm manufacturing joint venture for instance that will put it in a great position to take advantage of china's new policy's on formula manufacturing ownership.

I think this lack of information the market sees on sites such as next smallcap, marketindex, simplywallstreet etc when you google asx jat is the reason for this low SP.

When JATS EFY report hits these sites in a month or two it will be interesting.
DYOR GLTAH